Halozyme's Elektrofi Deal: Site-Of-Care Optionality (Rating Upgrade) [Seeking Alpha]
Halozyme Therapeutics, Inc. (HALO)
Last halozyme therapeutics, inc. earnings: 2/24 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
halozyme.com/investors/default.aspx
Company Research
Source: Seeking Alpha
HALO's acquisition of Elektrofi (Hypercon) extends IP into the 2040s, offering optionality but with uncertain long-term revenue durability. ENHANZE's U.S. patent expiry in 2027 raises post-2030 questions, but royalty streams and asset-light margins remain strong near-term. Balance sheet strength, an expanding royalty base, and upcoming catalysts (Hypercon trials, ENHANZE deals, MDASE litigation) underpin the current investment case. fcafotodigital/E+ via Getty Images Overview I last covered Halozyme ( HALO ) in September 2025. This is a company I 've followed for nearly two years now. As time has passed, I 've become more cautious. My caution is This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than fro
Show less
Read more
Impact Snapshot
Event Time:
HALO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HALO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HALO alerts
High impacting Halozyme Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HALO
News
- Jim Lang Elected to Halozyme's Board of DirectorsPR Newswire
- Halozyme granted injunction in Germany barring Merck's subcutaneous Keytruda [Seeking Alpha]Seeking Alpha
- Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany [Yahoo! Finance]Yahoo! Finance
- Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in GermanyPR Newswire
- Halozyme Therapeutics (NASDAQ:HALO) had its "sell" rating reaffirmed by analysts at The Goldman Sachs Group, Inc.. They now have a $56.00 price target on the stock.MarketBeat
HALO
Earnings
- 11/3/25 - Beat
HALO
Sec Filings
- 12/11/25 - Form 4
- 12/9/25 - Form 8-K
- 12/8/25 - Form 8-K
- HALO's page on the SEC website